Anti-atherosclerotic effect of incretin receptor agonists

被引:2
|
作者
Wang, Xin [1 ]
Yang, Xin [1 ]
Qi, Xiaoyan [2 ,3 ]
Fan, Gang [3 ,4 ]
Zhou, Lingzhi [3 ,5 ]
Peng, Zhengliang [6 ]
Yang, Jing [1 ,2 ,3 ]
机构
[1] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Metab & Endocrinol, Hengyang, Hunan, Peoples R China
[2] Shenzhen Nanshan Peoples Hosp, Dept Metab & Endocrinol, Shenzhen, Guangdong, Peoples R China
[3] Shenzhen Univ Hlth Sci Ctr, Affiliated Hosp 6, Shenzhen, Guangdong, Peoples R China
[4] Shenzhen Nanshan Peoples Hosp, Dept Urol, Shenzhen, Guangdong, Peoples R China
[5] Shenzhen Nanshan Peoples Hosp, Dept Pediat, Shenzhen, Guangdong, Peoples R China
[6] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Emergency, Hengyang, Hunan, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
incretin receptor agonists; type 2 diabetes mellitus; cardiovascular disease; atherosclerosis; vasculoprotective effects; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PEPTIDE-1 ANALOG LIRAGLUTIDE; ENDOTHELIAL-CELL DYSFUNCTION; ONCE-WEEKLY SEMAGLUTIDE; SMOOTH-MUSCLE-CELLS; END-PRODUCTS AGES; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; ATHEROSCLEROTIC LESIONS; VASCULAR ENDOTHELIUM;
D O I
10.3389/fendo.2024.1463547
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Incretin receptor agonists (IRAs), primarily composed of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide receptor agonists (GIPRAs), work by mimicking the actions of the endogenous incretin hormones in the body. GLP-1RAs have been approved for use as monotherapy and in combination with GIPRAs for the management of type 2 diabetes mellitus (T2DM). In addition to their role in glucose regulation, IRAs have demonstrated various benefits such as cardiovascular protection, obesity management, and regulation of bone turnover. Some studies have suggested that IRAs not only aid in glycemic control but also exhibit anti-atherosclerotic effects. These agents have been shown to modulate lipid abnormalities, reduce blood pressure, and preserve the structural and functional integrity of the endothelium. Furthermore, IRAs have the ability to mitigate inflammation by inhibiting macrophage activation and promoting M2 polarization. Research has also indicated that IRAs can decrease macrophage foam cell formation and prevent vascular smooth muscle cell (VSMC) phenotype switching, which are pivotal in atheromatous plaque formation and stability. This review offers a comprehensive overview of the protective effects of IRAs in atherosclerotic disease, with a focus on their impact on atherogenesis.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Lactobacilli and Bifidobacterium as anti-atherosclerotic agents
    Abdi, Milad
    Ghaleh, Hadi Esmaeili Gouvarchin
    Ranjbar, Reza
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 25 (08) : 934 - 946
  • [22] Potential Anti-Atherosclerotic Properties of Astaxanthin
    Kishimoto, Yoshimi
    Yoshida, Hiroshi
    Kondo, Kazuo
    MARINE DRUGS, 2016, 14 (02)
  • [23] Anti-atherosclerotic effect of traditional fermented cheese whey in atherosclerotic rabbits and identification of probiotics
    Nabi, Xin-Hua
    Ma, Chun-Yan
    Manaer, Tabusi
    Heizati, Mulalibieke
    Wulazibieke, Baheti
    Aierken, Latipa
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 16
  • [24] Proteomic analysis for anti-atherosclerotic effect of tetrahydroxystilbene glucoside in rats
    Yao, WenJuan
    Fan, WenJun
    Huang, Chao
    Zhong, Hui
    Chen, XiangFan
    Zhang, Wei
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (02) : 140 - 145
  • [25] PROSTACYCLIN ANALOGS AS ANTI-ATHEROSCLEROTIC DRUGS
    OREKHOV, AN
    TERTOV, VV
    SMIRNOV, VN
    LANCET, 1983, 2 (8348): : 521 - 521
  • [26] TRAPIDIL - A POTENTIAL ANTI-ATHEROSCLEROTIC AGENT
    SAUNDERS, RN
    HANDLEY, DA
    HAEMOSTASIS, 1982, 12 (1-2) : 67 - 67
  • [27] Anti-atherosclerotic mechanisms of statin therapy
    Babelova, Andrea
    Sedding, Daniel G.
    Brandes, Ralf P.
    CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (02) : 260 - 264
  • [28] Anti-atherosclerotic effect of traditional fermented cheese whey in atherosclerotic rabbits and identification of probiotics
    Xin-Hua Nabi
    Chun-Yan Ma
    Tabusi Manaer
    Mulalibieke Heizati
    Baheti Wulazibieke
    Latipa Aierken
    BMC Complementary and Alternative Medicine, 16
  • [29] NATURAL PRODUCTS FOR ANTI-ATHEROSCLEROTIC THERAPY
    Kirichenko, T.
    Orekhova, V.
    Myasoedova, V.
    Melnichenko, A.
    Sobenin, I.
    Orekhov, A.
    ATHEROSCLEROSIS, 2019, 287 : E152 - E152
  • [30] ARTIFICIAL HDL AS AN ANTI-ATHEROSCLEROTIC DRUG
    OREKHOV, AN
    MISHARIN, AY
    TERTOV, VV
    KHASHIMOV, KA
    POKROVSKY, SN
    REPIN, VS
    SMIRNOV, VN
    LANCET, 1984, 2 (8412): : 1149 - 1150